Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(33)
DRUG(6)
RADIATION(6)
BIOLOGICAL(1)
Laboratory Biomarker Analysis
5 trials
phase_1phase_1_2phase_2
fred-hutchinson-cancer-center, university-of-washington
Etoposide
3 trials
phase_1phase_1_2
fred-hutchinson-cancer-center, university-of-washington
Autologous Hematopoietic Stem Cell Transplantation
3 trials
phase_1phase_1_2
fred-hutchinson-cancer-center
Peripheral Blood Stem Cell Transplantation
2 trials
phase_1phase_1_2
fred-hutchinson-cancer-center
Melphalan
2 trials
phase_1phase_1_2
fred-hutchinson-cancer-center
Pharmacological Study
2 trials
phase_1phase_2
fred-hutchinson-cancer-center
Cytarabine
2 trials
phase_1phase_1_2
fred-hutchinson-cancer-center
Carmustine
2 trials
phase_1phase_1_2
fred-hutchinson-cancer-center

+25 more interventions

33 unique interventions4 categories

Analytics

Trial Phases

Phase 15
Phase 26

Trial Status

Completed2
Recruiting1
Terminated4
Other1

Role Distribution

Principal Investigator8
PI Rate100%

Activity Timeline

Clinical Trials (8)

NCT06442475Phase 2Recruiting
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
PrincipalinvestigatorStart date: 2024-08-29
NCT04257578Phase 1/2Active Not Recruiting
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedGrade 1 Follicular Lymphoma+5 more
PrincipalinvestigatorStart date: 2020-12-02
NCT02483000Phase 1Terminated
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Burkitt LymphomaCD20-Positive Neoplastic Cells PresentDiffuse Large B-Cell Lymphoma+4 more
PrincipalinvestigatorStart date: 2017-02-01
NCT02489123Phase 2Terminated
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Ann Arbor Stage I Mantle Cell LymphomaAnn Arbor Stage II Mantle Cell LymphomaAnn Arbor Stage III Mantle Cell Lymphoma+3 more
PrincipalinvestigatorStart date: 2015-08-11
NCT02227199Phase 1/2Completed
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
PrincipalinvestigatorStart date: 2014-10-10
NCT01921387Phase 1/2Completed
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent Mantle Cell Lymphoma+5 more
PrincipalinvestigatorStart date: 2013-10-09
NCT01434472Phase 2Terminated
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Post-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+4 more
PrincipalinvestigatorStart date: 2011-11-16
NCT00860171Phase 1Terminated
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin Lymphoma+3 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Recurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell LymphomaLymphoma, Large B-Cell, Diffuse+5 more

Worked with same sponsors:

Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)
Similarity Score6%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Recurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell LymphomaPost-Transplant Lymphoproliferative Disorder+1 more

Worked with same sponsors:

Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)+1 more
Similarity Score3%

Luhua (Michael) Wang

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Lymphoma, Mantle-CellRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Burkitt LymphomaLymphoma, Large B-Cell, DiffuseIndolent Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Mitchell S Cairo, MD

New York Medical College

Related
13 trials

Shared therapeutic areas:

Burkitt LymphomaLymphoma, Large B-Cell, DiffuseHigh Grade B-Cell Lymphoma
Similarity Score2%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score2%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score2%

Carlos Montalbán Sanz, MD

Hospital Universitario Ramon y Cajal

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score2%

Eulogio Conde García, MD

Hospital Marqués de Valdecilla

Related
2 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score2%

William Wegener, MD, PhD

Gilead Sciences

Related
12 trials

Shared therapeutic areas:

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-Cell
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (8)

Showing 8 of 8 trials

NCT06442475Phase 2PrincipalInvestigator

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
Recruiting
NCT04257578Phase 1/2PrincipalInvestigator

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedGrade 1 Follicular Lymphoma+5 more
Active Not Recruiting
NCT02483000Phase 1PrincipalInvestigator

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Burkitt LymphomaCD20-Positive Neoplastic Cells PresentDiffuse Large B-Cell Lymphoma+4 more
Terminated
NCT02489123Phase 2PrincipalInvestigator

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Ann Arbor Stage I Mantle Cell LymphomaAnn Arbor Stage II Mantle Cell LymphomaAnn Arbor Stage III Mantle Cell Lymphoma+3 more
Terminated
NCT02227199Phase 1/2PrincipalInvestigator

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Completed
NCT01921387Phase 1/2PrincipalInvestigator

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent Mantle Cell Lymphoma+5 more
Completed
NCT01434472Phase 2PrincipalInvestigator

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Post-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+4 more
Terminated
NCT00860171Phase 1PrincipalInvestigator

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin Lymphoma+3 more
Terminated

All 8 trials loaded